HUTCHMED and GSK announce $1.3B deal for KRAS-EGFR antibody conjugate
HUTCHMED announced a licensing and co-development deal with GSK for a novel KRAS-EGFR antibody conjugate. The agreement includes $1.3 billion in potential value, with HUTCHMED leading phase I trials and GSK taking over ex-China development.
HUTCHMED said it has reached a licensing and co-development agreement with GSK for a KRAS-EGFR antibody conjugate, a deal it said validates the ATTC platform and is intended to speed global development. The agreement carries $1.3 billion in potential value, with HUTCHMED to lead phase I trials and GSK to take over ex-China deve…